Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight Therapeutics Announces Increase of Previously Announced "Bought Deal" Private Placement of Special Warrants to $180 Million

Marketwired March 21, 2014

Knight Therapeutics Enters into Agreement for a $75 Million "Bought Deal" Private Placement of Special Warrants

Marketwired March 21, 2014

Knight Therapeutics (V.GUD) obtains US FDA approval for Impavido(R), up 9%

Gaalen Engen March 20, 2014

Knight Therapeutics Inc. Announces FDA Approval for Impavido(R) (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis

Marketwired March 19, 2014

Knight Therapeutics Completes Previously Announced "Bought Deal" Private Placement of Special Warrants for Gross Proceeds of Approximately $75 Million

Marketwired March 19, 2014

Knight Therapeutics Announces Over-Allotment Option in Previously Announced "Bought Deal" Private Placement of Special Warrants, Bringing Expected Proceeds to $75 Million

Marketwired March 6, 2014

Knight Therapeutics Enters Into Agreement for a $71 Million "Bought Deal" Private Placement of Special Warrants

Marketwired March 5, 2014

IIROC Trading Resumption - GUD

Canada NewsWire February 28, 2014

IIROC Trade Resumption - Knight Therapeutics Inc.

Newsfile February 28, 2014

Knight Therapeutics Inc. Appoints New CFO

Marketwired February 28, 2014

Knight Therapeutics Inc. to Begin Trading on March 3, 2014

Marketwired February 28, 2014

IIROC Trading Halt - GUD

Canada NewsWire February 28, 2014